An observational study in HIV Seropositivity, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Completed at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
The ageing process is known to be accelerated in HIV-infected patients, compared to the general population.
Normal age-related hearing loss (presbyacusia) is a frequent phenomenon, affecting more than 70% of people above 65 years. It is believed to be mostly the consequence of a mitochondrial damage caused by oxidative stress.
Risk factors for accelerated age-related hearing loss are present in many HIV-infected patients : chronic inflammation, smoking, diabetes, etc.
The global aim is to measure the prevalence of presbyacusia in a well controlled HIV positive population in France, and to compare it to HIV negative controls matched for age and sex.
90 HIV positive patients and 90 age- and sex- matched HIV negative controls will undergo a screening for presbyacusia (pure-tone, speech and evoked-response audiometry).
We expect to find an increased prevalence of presbyacusia in HIV-infected patients, as compared to controls matched for age and sex.
210 studies on the registry are indexed under HIV Seropositivity; 10 are open to participants now.
This study's enrollment of 206 is close to the median of 223 across 62 observational studies indexed under HIV Seropositivity.
Browse HIV Seropositivity studies →Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 311 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients followed for HIV infection in the department of infectious diseases of Saint-Antoine hospital or Bichat hospital and/or by a private HIV-specialized physician in Paris, France
Exclusion Criteria:
HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
non-HIV (matched for age and gender)
hearing loss at several frequencies
Measurement by audiometry (pure tone and speech audiometry at 500Hz, 1000Hz, 2000Hz, 3000Hz and 8000 Hz), expressed in dB.
Time frame: Baseline
threshold for speech intelligibility
measured by speech audiometry
Time frame: Baseline
Proportion of patients with neuropathic hearing loss
Time frame: Baseline
Interval I-V on the evoked-response audiogram
Time frame: Baseline
Maximum speech intelligibility
Measured by speech audiometry
Time frame: Baseline
Proportion of patients with age-related hearing loss
Time frame: Baseline
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild